George Yancopoulos
Co-founder, President, and Chief Scientific Officer of Regeneron Pharmaceuticals
George Yancopoulos is a Greek-American biomedical scientist, inventor, and biotechnology executive, widely regarded as one of the leading innovators in modern drug discovery. He is the co-founder, President, and Chief Scientific Officer of Regeneron Pharmaceuticals, where he has played a central role in building one of the world’s most successful biotechnology companies focused on antibody-based and genetic medicines.
Dr. Yancopoulos earned his undergraduate, medical, and doctoral degrees from Columbia University, where he developed an early interest in molecular biology and translational medicine. Over his career, he has led the discovery and development of numerous breakthrough therapies, including treatments for retinal diseases, inflammatory disorders, cancer, and infectious diseases. Under his scientific leadership, Regeneron developed landmark medicines such as Eylea and Dupixent, as well as a rapid antibody therapy response during the COVID-19 pandemic.
An inventor on hundreds of patents and author of many scientific publications, Dr. Yancopoulos is recognized internationally for advancing technologies that accelerate the transformation of basic scientific discoveries into life-changing therapies for patients worldwide.